Biomedical subjects
L Denis
Publications and source records attributed to L Denis.
The TNM classification in clinical research.
Explore the source record for details and available documents.
The chemotherapy of disseminated testicular non-seminomatous germ cell tumors and the clinical research of the EORTC Genitourinary Group.
Explore the source record for details and available documents.
The diagnostic work-up of the undescended testis.
Explore the source record for details and available documents.
An LH-RH analogue (Zoladex) in the management of carcinoma of the prostate: a preliminary report comparing daily subcutaneous injections with monthly depot injections.
The luteinizing hormone releasing hormone, Zoladex, has been used in three centres, Pontefract, Antwerp and Mistelbach, to treat carcinoma of the prostate. An initial protocol using a soluble daily injection has been followed by a second study employing a monthly administered depot preparation. After an initial stimulation it has been shown that both daily and monthly injections reduce plasma testosterone to castrate levels. Circulating luteinizing hormone levels are also initially stimulated and then suppressed. Treatment toxicity has been minimal and in these short term studies reduction of acid phosphatase and subjective and objective tumour responses have been similar to those expected from effective hormonal therapy of prostatic cancer.
[Indications and limitations of ultrasound and axial computed tomography in urologic oncology].
Explore the source record for details and available documents.
Mitomycin C therapy in superficial bladder cancer.
Explore the source record for details and available documents.
[Reduction phalloplasty using the bilateral Nesbit technic. A case of congenital hypertrophy of the adrenal glands].
Explore the source record for details and available documents.
Clinical applications of ketoconazole in prostatic cancer.
Explore the source record for details and available documents.
A patient with testis seminoma, sarcoidosis, and neutropenic enterocolitis.
Seminoma and sarcoidosis do not seem to be associated diseases, judging from epidemiologic data. The presence of these two diseases in the patient whose case is reported may have been coincidental. It was observed, however, that when the testis tumor appeared in this patient, the longstanding sarcoid lesions significantly increased. The patient developed neutropenic enterocolitis after chemotherapy for a non-hematologic malignancy.
Estramustine phosphate in prostate cancer. EORTC experience: preliminary results of Protocol 30762.
Explore the source record for details and available documents.
[Hormonal manipulation of disseminated prostatic cancer].
Explore the source record for details and available documents.
Current status of bladder cancer protocols in the EORTC Genito-Urinary Group.
This report gives an updated account of the phase II and III bladder studies conducted by the Genito-Urinary Cooperative Group of the EORTC. All phase II studies screen for activity in patients with measurable advanced disease. All phase III studies are randomized studies aimed at controling the recurrence rate of superficial bladder tumors. This long term planning on chemotherapy and chemoprevention will be continued in an orderly fashion and expanded with the evaluation of radiotherapy, surgery and/or immunology regimens for tumor control in the near future.
Therapeutic use of mitomycin C in bladder cancer.
Explore the source record for details and available documents.
Ultrasonography and computed tomography in the staging of bladder and prostate cancers.
Explore the source record for details and available documents.
[Value of preoperative chemotherapy in the treatment of invasive cancer of the bladder].
Explore the source record for details and available documents.
Anaphylactic reactions to repeated intravesical instillation with cisplatin.
Explore the source record for details and available documents.
Vindesine in advanced renal cancer. A study of the EORTC Genito-urinary Tract Cancer Cooperative Group.
Vindesine at a dose of 3 mg/m2 i.v. once a week failed to produce responses in 24 adequately treated patients with measurable advanced renal carcinoma. Leukopenia and peripheral neurotoxicity were the most often observed side-effects. On the basis of the negative result, the application of vindesine in this disease is not recommended.